City Research Online

Compulsory Licensing of Patents: the Bayer-Natco Case

Bonadio, E. (2012). Compulsory Licensing of Patents: the Bayer-Natco Case. European Intellectual Property Review, 34(10), pp. 719-728.


On 9th March 2012 the Indian Controller of Patents granted the first compulsory licence in India. Indian generics producer Natco Pharma Ltd. has been granted the right to produce and sell in India Bayer’s patented medicine “Sorafenib”, which is useful for treating advanced stage liver and kidney cancer.

After a brief introduction on cumpulsory licences under the TRIPS Agreement and the Paris Convention, the author verifies whether the decision of the Controller of Patents satisfies the conditions set forth by the these international treaties in relation to compulsory licences. He concludes inter alia that the ruling might be in violation of the non discrimination principle enshrined in Article 27(1) TRIPS.

General comments are also made about the role of compulsory licensing in guaranteeing the availability of patented products to a wide range of consumers and in general the transfer and dissemination of the associated technology.

Publication Type: Article
Subjects: K Law > K Law (General)
Departments: The City Law School
[thumbnail of Compulsory Licensing of Patents.pdf]
PDF - Accepted Version
Download (255kB) | Preview


Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email


Downloads per month over past year

View more statistics

Actions (login required)

Admin Login Admin Login